Lifeboat Foundation

Imagine if your manager could know whether you actually paid attention in your last Zoom meeting. Or, imagine if you could prepare your next presentation using only your thoughts. These scenarios might soon become a reality thanks to the development of brain-computer interfaces (BCIs).

To put it in the simplest terms, think of a BCI as a bridge between your brain and an external device. As of today, we mostly rely on electroencephalography (EEG) — a collection of methods for monitoring the electrical activity of the brain — to do this. But, that’s changing. By leveraging multiple sensors and complex algorithms, it’s now becoming possible to analyze brain signals and extract relevant brain patterns. Brain activity can then be recorded by a non-invasive device — no surgical intervention needed. In fact, the majority of existing and mainstream BCIs are non-invasive, such as wearable headbands and earbuds.

The development of BCI technology was initially focused on helping paralyzed people control assistive devices using their thoughts. But new use cases are being identified all the time. For example, BCIs can now be used as a neurofeedback training tool to improve cognitive performance. I expect to see a growing number of professionals leveraging BCI tools to improve their performance at work. For example, your BCI could detect that your attention level is too low compared with the importance of a given meeting or task and trigger an alert. It could also adapt the lighting of your office based on how stressed you are, or prevent you from using your company car if drowsiness is detected.

Are you ready?

“if you were the type of geek, growing up, who enjoyed taking apart mechanical things and putting them back together again, who had your own corner of the garage or the basement filled with electronics and parts of electronics that you endlessly reconfigured, who learned to solder before you could ride a bike, your dream job would be at the Intelligent Systems Center of the Applied Physics Laboratory at Johns Hopkins University. Housed in an indistinct, cream-colored building in a part of Maryland where you can still keep a horse in your back yard, the ISC so elevates geekdom that the first thing you see past the receptionist’s desk is a paradise for the kind of person who isn’t just thrilled by gadgets, but who is compelled to understand how they work.”

Continue reading “The brain-computer interface is coming, and we are so not ready for it” »

Individual frequency can be used to specifically influence certain areas of the brain and thus the abilities processed in them — solely by electrical stimulation on the scalp, without any surgical intervention. Scientists at the Max Planck Institute for Human Cognitive and Brain Sciences have now demonstrated this for the first time.

Stroke, Parkinson’s disease and depression — these medical illnesses have one thing in common: they are caused by changes in brain functions. For a long time, research has therefore been conducted into ways of influencing individual brain functions without surgery in order to compensate for these conditions.

Scientists at the Max Planck Institute for Human Cognitive and Brain Sciences in Leipzig have taken a decisive step. They have succeeded in precisely influencing the functioning of a single area of the brain. For a few minutes, they inhibited exactly the area that processes the sense of touch by specifically intervening in its rhythm. As a result, the area that was less networked with other brain regions, its so-called functional connectivity, decreased, and thus also the exchange of information with other brain networks.

Tesla and CureVac have collaborated on a patent for an RNA bioreactor.

Although there are no human vaccines made with RNA, the technology could break through on COVID-19 (coronavirus).

The bioreactor works by combining chemical agents in an egg-shaped magnetic mixer.

Continue reading “Tesla Has Been Working On an RNA Bioreactor” »

A study published in BMC Cancer analyzed the relationship between education level and survival in multiple myeloma and observed that patients with lower education levels may have lower survival rates.

A study observed that multiple myeloma patients with lower education levels may have lower survival rates compared to those with higher education levels.

According to the University of Minnesota trial data supports dexamethasone over Hydroxychloroquine:

Data from a large randomized controlled trial in the United Kingdom showing a benefit from use of the steroid dexamethasone in hospitalized COVID-19 patients was released today in the New England Journal of Medicine (NEJM), while two more studies show no benefit for the malaria drug hydroxychloroquine.

The NEJM data, which were originally reported in a press release in mid-June by the chief investigators of the RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial after an interim analysis, show that in patients needing mechanical ventilation, dexamethasone reduced deaths by 36% compared with usual care. In patients receiving oxygen, the incidence of death was 18% lower for patients on dexamethasone.

Continue reading “Trial data support dexamethasone, but not hydroxychloroquine, for COVID-19” »

Scientists discover that oxytocin could be used to treat cognitive disorder like Alzheimer’s disease.

Alzheimer’s disease is a progressive disorder in which the nerve cells (neurons) in a person’s brain and the connections among them degenerate slowly, causing severe memory loss, intellectual deficiencies, and deterioration in motor skills and communication. One of the main causes of Alzheimer’s is the accumulation of a protein called amyloid β (Aβ) in clusters around neurons in the brain, which hampers their activity and triggers their degeneration.

Studies in animal models have found that increasing the aggregation of Aβ in the hippocampus—the brain’s main learning and memory center—causes a decline in the signal transmission potential of the neurons therein. This degeneration affects a specific trait of the neurons, called ‘synaptic plasticity,’ which is the ability of synapses (the site of signal exchange between neurons) to adapt to an increase or decrease in signaling activity over time. Synaptic plasticity is crucial to the development of learning and cognitive functions in the hippocampus. Thus, Aβ and its role in causing cognitive memory and deficits have been the focus of most research aimed at finding treatments for Alzheimer’s.

Now, advancing this research effort, a team of scientists from Japan, led by Professor Akiyoshi Saitoh from the Tokyo University of Science, has looked at oxytocin, a hormone conventionally known for its role in the female reproductive system and in inducing the feelings of love and well-being. “Oxytocin was recently found to be involved in regulating learning and memory performance, but so far, no previous study deals with the effect of oxytocin on Aβ-induced cognitive impairment,” Prof Saitoh says. Realizing this, Prof Saitoh’s group set out to connect the dots. Their findings are published in Biochemical and Biophysical Research Communication.

Continue reading “‘Love hormone’ oxytocin could be used to treat cognitive disorders like Alzheimer’s” »

Bioprinting could be used for testing potential treatments for Covid-19, cancer and other diseases.

Bioprinting’s importance for pharmaceutical analysis is paramount now, not only for potential Covid-19 treatments, but also for testing treatments for cancer and other diseases. Dr. Atala says that the organoids allow researchers to analyze a drug’s impact on an organ “without the noise” of an individual’s metabolism.

He cited Rezulin, a popular diabetes drug recalled in 2000 after there was evidence of liver failure. His lab tested an archived version of the drug, and Dr. Atala said that within two weeks, the liver toxicity became apparent. What accounts for the difference? An organoid replicates an organ in its purest form and offers data points that might not occur in clinical trials, he said, adding that the testing is additive to, rather than in lieu of, clinical trials.

“‘Aurora will enable us to explore new frontiers in artificial intelligence and machine learning,’ said Narayanan ‘Bobby’ Kasthuri, assistant professor of neurobiology at the University of Chicago and researcher at Argonne. ‘This will be the first time scientists have had a machine powerful enough to match the kind of computations the brain can do.’”

Super computer Aurora will help map the human brain at “quintillion—or one billion billion—calculations per second, 50 times quicker than today’s most powerful supercomputers.”

Note: the article discusses implications beyond neuroscience.

Continue reading “New Argonne supercomputer, built for next-gen AI, will be most powerful in U.S.” »